Fiduciary Financial Group LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL)

Fiduciary Financial Group LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,746 shares of the biotechnology company's stock, valued at approximately $232,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of EXEL. Tallon Kerry Patrick acquired a new position in Exelixis in the fourth quarter worth about $2,619,000. Empowered Funds LLC acquired a new position in shares of Exelixis during the fourth quarter valued at approximately $7,455,000. Entropy Technologies LP lifted its holdings in shares of Exelixis by 18.7% in the fourth quarter. Entropy Technologies LP now owns 21,731 shares of the biotechnology company's stock valued at $724,000 after buying an additional 3,431 shares during the period. Savant Capital LLC boosted its position in shares of Exelixis by 1.2% during the 4th quarter. Savant Capital LLC now owns 70,831 shares of the biotechnology company's stock valued at $2,359,000 after purchasing an additional 849 shares in the last quarter. Finally, Sapient Capital LLC acquired a new stake in shares of Exelixis during the 4th quarter valued at $256,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Piper Sandler boosted their price target on shares of Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Stephens restated an "equal weight" rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Bank of America boosted their target price on shares of Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, Barclays raised their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $39.76.

Exelixis Stock Performance

NASDAQ:EXEL traded up $0.17 during mid-day trading on Thursday, hitting $41.60. 560,805 shares of the stock were exchanged, compared to its average volume of 2,340,944. The firm's 50-day simple moving average is $39.41 and its 200 day simple moving average is $36.79. The stock has a market capitalization of $11.34 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a fifty-two week low of $21.36 and a fifty-two week high of $48.85.

Insider Buying and Selling

In other news, Director Jack L. Wyszomierski sold 7,535 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total transaction of $324,683.15. Following the completion of the transaction, the director now owns 358,882 shares of the company's stock, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dana Aftab sold 1,508 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the transaction, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. The trade was a 0.22% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 458,113 shares of company stock worth $21,024,817. Company insiders own 2.82% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.